The massive market transformation this month that some on Wall Street called a "once in a decade opportunity" might have just been a one-off technical move because of taxes.Marketsread more
The Pentagon will deploy U.S. forces to the Middle East on the heels of the attack on Saudi Arabian oil facilities, United States Secretary of Defense Mark Esper announced...Defenseread more
CNBC did a deep dive through the most recent Wall Street research to find stocks that analysts say are underappreciated.Marketsread more
Shares of MasterCard are up 46% this year, and 1120% since 2011, getting a boost from the strong U.S. consumer.Investingread more
CNBC sat in on an "empathy training" at Amazon PillPack's Somerville offices, which is part of new hire orientation.Technologyread more
Trade with China is the 'big unknown' for the Federal Reserve as it decides how best to support the U.S. economy, says Council on Foreign Relations Director of International...Futures Nowread more
Lobbying experts said the visit is likely an attempt to be in lawmakers' ears as they consider legislation that would impact Facebook.Technologyread more
Yardeni Research's Edward Yardeni believes the U.S. economy is picking up steam.Trading Nationread more
Iran's audacious drone and cruise missile attack on Saudi Arabia's oil producing facilities has provided a critical test yet for the Trump administration's foreign policy. A...Politicsread more
Chinese trade negotiators suddenly canceled a visit to meet U.S. farmers after they wrapped up trade talks in Washington this week.Marketsread more
The Trump administration should make the rising cost of medicine a leading issue in trade talks with countries around the world, Mount Sinai Health System CEO Kenneth Davis told CNBC on Friday.
"We marvel at the fact that U.S. drug costs are two to six times higher than they are in the rest of the world," he said on "Power Lunch."
"What I don't understand is why in trade talk don't we make this a prominent issue?" he added. "Why don't we say, 'You guys can't allow the U.S. consumer to be subsidizing all the R&D costs of drug development. You've got to pay your fair share. We want to see you add 20% to the cost of your drugs.'"
Because the United States is a free market, prices are higher. Meanwhile, in other parts of the world, governments pay for the drugs and they set the price, Davis said.
If other countries pick up more of the cost, then American consumers should be able to contribute less. Of course, for the plan to work, the manufacturers also have to agree not to raise U.S. prices, but instead lower them in proportion to the increased pay they are getting from other countries, he noted.
"The U.S. is being unfairly penalized here for the cost of drugs around the world."
Fixing sky-high drug costs is an issue both Republicans and Democrats have rallied around.
For one, Sen. Bernie Sanders, a Vermont independent who is making another run for the White House, has vowed to slash prices in half if he wins the 2020 election.
President Donald Trump has also called out drugmakers and has put forth some proposals.
One calls for an internal pricing index (IPI) that would determine what Medicare pays for certain medicines based on the prices set in a handful of other countries. A proposed version of the rule is expected in August. However, on Thursday, Merck CEO Ken Frazier said if it is implemented, there will be legal challenges.
Also, last month the White House announced pharmaceutical companies will be required to disclose the price of their prescription drugs in TV commercials. Three U.S. drugmakers, including Merck, have sued the U.S. Department of Health and Human Services over the new regulation.
— Reuters contributed to this report.